Gilead Sciences Newswire (Page 9)

Gilead Sciences Newswire (Page 9)

Comprehensive Real-Time News Feed for Gilead Sciences. (Page 9)

Results 161 - 180 of 5,283 in Gilead Sciences

  1. Massachusetts Warns Gilead About Hepatitis Drug PricesRead the original story

    Jan 29, 2016 | Chemical and Engineering News

    Gilead Sciences has received a letter of warning from the attorney general of Massachusetts saying that levying high prices for its new hepatitis C virus drugs may constitute an unfair trade practice in violation of Massachusetts law and that the state may pursue legal action if the company does not lower the prices. Noting that the drugs, Sovaldi and Harvoni, costing $84,000 and $94,500, respectively, per course of treatment, offer a cure to patients, .

    Comment?

  2. 3 Stocks We're Watching in the Second QuarterRead the original story w/Photo

    Apr 3, 2016 | The Motley Fool

    ... already priced in... or not? George Budwell : The stock that has my full attention in the second quarter is Gilead Sciences . Gilead is a blue chip biotech that sets the tone for the industry in many ways because of its explosive growth over the ...

    Comment?

  3. ContraVir's CMX157 Bests Gilead's Tenofovir AF (TAF) Against Hep B...Read the original story

    Mar 28, 2016 | BioSpace

    ... as part of a four-drug combination therapy for HIV-1 (GenvoyaA ), and is currently under development by Gilead Sciences Inc. (GILD) for treating chronic hepatitis B infection. ContraVir recently initiated a Phase 1/2a clinical study of CMX157, which ...

    Comment?

  4. For a Possible Gilead-Celgene Deal, Let Us Count the WaysRead the original story

    Mar 30, 2016 | BioSpace

    March 30, 2016 By Mark Terry , BioSpace.com Breaking News Staff Both Summit, N.J.-based Celgene Corporation and Forest City, Calif.-based Gilead are companies investors and analysts are keeping an eye on , but some analysts wonder if Celgene might be an acquisition target for Gilead. Celgene recently reported its 2016 financial outlook and preliminary 2015 financials, with projected net product sales this year of $10.5 billion to $11 billion, a 17 percent increase year-over-year.

    Comment?

  5. Morgan Stanley Reiterates "Equal Weight" Rating for Gilead Sciences, Inc.Read the original story w/Photo

    Apr 1, 2016 | AmericanBankingNews.com

    ... price objective would indicate a potential upside of 17.93% from the stock's previous close. In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the company's stock in a transaction dated Monday, March 14th. The shares were sold ...

    Comment?

  6. Stocks slip, led by energy and materials companiesRead the original story w/Photo

    Mar 23, 2016 | 12NewsNow.Com

    ... after the software maker delivered disappointing forecasts. The stock fell $2.45 to $73.26. PHARMA SUIT: Gilead Sciences fell 3.5 percent after a federal jury in California ruled in favor of rival Merck & Co. in a high-stakes lawsuit over patents ...

    Comment?

  7. Stocks slip, led by energy and materials companiesRead the original story w/Photo

    Mar 23, 2016 | Seattle Post-Intelligencer

    ... after the software maker delivered disappointing forecasts. The stock fell $2.45 to $73.26. PHARMA SUIT: Gilead Sciences fell 3.5 percent after a federal jury in California ruled in favor of rival Merck & Co. in a high-stakes lawsuit over patents ...

    Comment?

  8. Stocks decline broadly at midday, led by energy, materialsRead the original story w/Photo

    Mar 23, 2016 | The Tribune

    ... after the software maker delivered disappointing forecasts. The stock fell $3.38 to $72.33. PHARMA SUIT: Gilead Sciences fell 3.7 percent after a federal jury in California ruled in favor of rival Merck & Co. in a high-stakes lawsuit over patents ...

    Comment?

  9. My Thoughts On Gilead Sciences' Patent LossRead the original story w/Photo

    Mar 23, 2016 | Seeking Alpha

    A significant news event broke yesterday pertaining to the ongoing patent dispute between Gilead Sciences and Merck . The jury found that GILD indeed infringes on a previous patent and will now deliberate on damages.

    Comment?

  10. Likely Next Steps In Gilead And Merck LitigationRead the original story w/Photo

    Mar 23, 2016 | The Biotech Stock Blog

    The royalty number has not yet been decided, and could be much lower than the 10 percent royalty that Merck is seeking. Gilead Sciences received some unfortunate news this morning when competitors Merck and Ionis Pharmaceuticals received a favorable ruling that allowed for the litigation to proceed.

    Comment?

  11. Stocks Are Modestly Lower as Crude DeclinesRead the original story w/Photo

    Mar 23, 2016 | TheStreet.com

    ... . jumped more than 2% after a federal jury in California ruled in its favor in a lawsuit against rival Gilead Sciences over several key hepatitis C patents. Merck accused Gilead of infringing on patents it filed over a decade ago, claiming Gilead's ...

    Comment?

  12. Stocks decline broadly in early trading in USMar 23, 2016,Read the original story w/Photo

    Mar 23, 2016 | The San Diego Union-Tribune

    ... after the software maker delivered disappointing forecasts. The stock fell $2.72 to $72.99. PHARMA SUIT: Gilead Sciences fell 2.7 percent after a federal jury in California ruled in favor of rival Merck & Co. in a high-stakes lawsuit over patents ...

    Comment?

  13. Us Stocks-Wall St set to open flat as investors keep off riskRead the original story w/Photo

    Mar 23, 2016 | Reuters

    ... in premarket trading after the world's largest footwear maker reported quarterly revenue below estimates. Gilead Sciences was down 2.4 percent at $91.40 after a federal jury upheld the validity of two Merck patents in a high-profile dispute over ...

    Comment?

  14. Stocks Extend Drop as Crude Tumbles Toward $40Read the original story w/Photo

    Mar 23, 2016 | TheStreet.com

    ... jumped more than 2% after a federal jury in California ruled in its favor in a lawsuit against rival Gilead Sciences over several key hepatitis C patents. Merck accused Gilead of infringing on patents it filed over a decade ago, claiming Gilead's ...

    Comment?

  15. Stock Futures Flat as Markets Move on From Brussels AttackRead the original story w/Photo

    Mar 23, 2016 | TheStreet.com

    ... 2% in premarket trading after a federal jury in California ruled in its favor in a lawsuit against rival Gilead Sciences over several key hepatitis C patents. Merck accused Gilead of infringing on patents it filed over a decade ago, claiming ...

    Comment?

  16. Gilead Sciences, Inc. (GILD) Price Target Cut to $116.00Read the original story w/Photo

    Mar 23, 2016 | AmericanBankingNews.com

    ... investors have recently bought and sold shares of the company. Norges Bank purchased a new position in Gilead Sciences during the fourth quarter worth $1,308,213,000. Agran Libbie increased its position in Gilead Sciences by 10,050.3% in the fourth ...

    Comment?

  17. Credit Suisse Cuts Gilead Sciences, Inc. (GILD) Price Target to $116.00Read the original story w/Photo

    Mar 23, 2016 | AmericanBankingNews.com

    ... Several other brokerages also recently commented on GILD. Zacks Investment Research downgraded shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Tuesday, December 29th. Barclays restated an "overweight" rating ...

    Comment?

  18. Gilead loses: San Jose jury says Merck wins chance for royalties on hepatitis C cureRead the original story w/Photo

    Mar 22, 2016 | San Jose Mercury News

    Merck & Co. won a jury verdict in San Jose federal court that allows it to seek royalties from Gilead Sciences for the drugs that have dominated the hepatitis C market with $20 billion in U.S. sales since 2013.

    Comment?

  19. Gilead Sciences, Inc. (GILD) Downgraded by Vetr Inc.Read the original story w/Photo

    Mar 22, 2016 | AmericanBankingNews.com

    ... weighed in on GILD. Piper Jaffray restated a "buy" rating and set a $134.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 2nd. Jefferies Group began coverage on Gilead Sciences in a research note on Monday, ...

    Comment?

  20. Jury finds for Merck in hepatitis drug fight with GileadRead the original story w/Photo

    Mar 22, 2016 | The Tribune

    A federal jury in California has ruled in favor of drugmaker Merck & Co. in a high-stakes lawsuit against rival Gilead Sciences Inc. over patents for lucrative new drugs that rapidly cure hepatitis C. Merck accused Gilead of infringing on patents it filed over a decade ago, claiming Gilead's sofosbuvir infringes on those patents.

    Comment?